# Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.

> **NCT04077905** · PHASE3 · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 160 (estimated)

## Conditions studied

- Hemophagocytic Lymphohistiocytosis

## Interventions

- **DRUG:** Pegylated liposomal doxorubicin
- **DRUG:** Etoposide
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT04077905
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-31
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04077905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04077905, "Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04077905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*